Edition:
United Kingdom

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.09USD
8:59pm GMT
Change (% chg)

$0.27 (+7.07%)
Prev Close
$3.82
Open
$3.89
Day's High
$4.09
Day's Low
$3.89
Volume
821
Avg. Vol
22,757
52-wk High
$8.61
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Novus Therapeutics Q3 Loss Per Share $0.37
1:00pm GMT 

Nov 13 (Reuters) - Novus Therapeutics Inc ::NOVUS THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.37.NOVUS BELIEVES THAT ITS CURRENT CASH WILL BE SUFFICIENT TO COMPLETE PLANNED PHASE I PROGRAM.  Full Article

Novus Therapeutics Reports Q4 Loss Per Share $0.30
Monday, 2 Apr 2018 

April 2 (Reuters) - Novus Therapeutics Inc ::YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.30.  Full Article

Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics As Of March 9
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Novus Therapeutics Inc ::ANDREW I. MCDONALD REPORTS 12.24 PERCENT PASSIVE STAKE IN NOVUS THERAPEUTICS INC AS OF MARCH 9, 2018 - SEC FILING‍​.  Full Article

Novus Therapeutics Inc reported Q3 $0.43 loss per share​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​.  Full Article

Novus Therapeutics reports third quarter 2017 results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics reports third quarter 2017 results.Q3 loss per share $0.43.  Full Article

Novus Therapeutics reports Q2 loss per share $1.32
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Novus Therapeutics Inc -:Novus Therapeutics reports second quarter 2017 results.Q2 loss per share $1.32.  Full Article

Ran Nussbaum reports 11.3 pct passive stake in Novus Therapeutics as of May 9
Thursday, 25 May 2017 

May 25 (Reuters) - Novus Therapeutics Inc :Ran nussbaum reports 11.3 percent passive stake in novus therapeutics inc as of may 9, 2017 - sec filing.  Full Article

Peregrine Ventures Management reports 8.9 percent passiave stake in Novus Therapeutics as of May 9
Monday, 22 May 2017 

May 22 (Reuters) - Peregrine Ventures Management Ltd :Peregrine Ventures Management Ltd reports a 8.9 percent passiave stake in Novus Therapeutics Inc as of May 9, 2017 - sec filing.  Full Article

Tokai pharmaceuticals inc says under terms of deal co may be required to pay Otic termination fee of $1 million
Thursday, 22 Dec 2016 

Tokai Pharmaceuticals Inc :Tokai Pharmaceuticals Inc says co may be required to pay Otic a termination fee of $1 million, or Otic may be required to pay co termination fee of $1.5 million.  Full Article

Tokai Pharmaceuticals and Otic Pharma enter into share purchase deal
Thursday, 22 Dec 2016 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals and Otic Pharma enter into share purchase agreement . Tokai Pharmaceuticals Inc says upon exchange, it is expected that existing tokai stockholders will own approximately 40% of combined company . Tokai Pharmaceuticals - entered into a definitive share purchase agreement under which shareholders of otic pharma will become majority owners of tokai . Tokai Pharmaceuticals Inc - gregory j. Flesher to be named president and chief executive officer of combined company . Tokai Pharmaceuticals Inc - shareholders of otic pharma will receive a total of 32.2 million shares of newly issued tokai common stock . Transaction has been unanimously approved by boards of directors of both companies and shareholders of otic pharma . Tokai Pharmaceuticals Inc says existing otic pharma shareholders owning approximately 60% of combined company . Tokai Pharmaceuticals - upon close of transaction, board of combined cowill consist of 7 members, 3 to be designated by tokai, 4 to be designated by otic pharma .Tokai Pharmaceuticals - an otic pharma investor syndicate has committed to invest $7 million of additional capital in connection with share purchase agreement.  Full Article